Skip to main content

News & Events

News & Announcements

CEVEC and Paragon Bioservices enter into comprehensive collaboration to roll out CAP® technologies in North America

Cologne, Germany and Baltimore, MD, USA, June 6, 2016 – CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors and Paragon Bioservices, Inc., a leader in the manufacturing of biopharmaceuticals and vaccines, today announced that the companies signed a collaboration and license agreement to jointly establish CEVEC’s proprietary CAP® technologies as a new industry standard for the scalable production of viral gene therapy vectors in North America.

Read the full article...